Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas
NCT ID: NCT01807052
Last Updated: 2016-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
34 participants
OBSERVATIONAL
2009-11-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
NCT01807143
Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas
NCT01802125
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
NCT01374672
Study of Blood Samples From Patients With Osteosarcoma
NCT00954473
Assessing Clinical Trial Experiences of Patients With Osteosarcoma
NCT05535283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBSERVATIONAL STUDY MODEL: Case-only
TIME PERSPECTIVE: Retrospective
BIOSPECIMEN RETENTION: Samples without DNA
BIOSPECIMEN DESCRIPTION: Tissue samples obtained from Cooperative Human Tissue Network (CHTN)
STUDY POPULATION DESCRIPTION: Patients enrolled on P9754 and AOST0121 clinical trials
SAMPLING METHOD: Non-probability sample
PRIMARY OBJECTIVES:
I. To determine if there is differential expression of tumor factor (TF) among patients with osteosarcoma.
II. To determine if there is an association between overall survival and disease free survival and the extent of TF expression.
III. To determine if TF expression correlates with presence of gross metastatic disease at presentation, and development of subsequent metastases.
OUTLINE:
Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational
Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
laboratory biomarker analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laboratory biomarker analysis
Correlative studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* P9754 clinical trial for patients with non-metastatic osteosarcoma
* AOST0121 clinical trial for patients with metastatic or recurrent osteosarcoma
39 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Ranalli, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Oncology Group
Monrovia, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2013-00112
Identifier Type: REGISTRY
Identifier Source: secondary_id
COG-AOST10B2
Identifier Type: OTHER
Identifier Source: secondary_id
AOST10B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.